Guillain Barré Syndrome, Myasthaenia Gravis, Myositis, Neuropathy, Parsonage Turner Syndrome
Conditions
Brief summary
MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors. With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis. Yet, so far, these complications have only been documented in a few single case reports. Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.
Interventions
OTHERNo Interventions
no intervention
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with neuromuscular complications of MEK inhibitors used alone or in combination * Age \> 18 years
Exclusion criteria
* Refusal of data collection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type of neuromuscular complications | up to 8 years |
Secondary
| Measure | Time frame |
|---|---|
| Time to onset after introduction of MEK inhibitors | up to 8 years |
| Severity of neuromuscular complications | up to 8 years |
| Progression with or without treatment | up to 8 years |
| Reintroduction of MEK inhibitors | up to 8 years |
Countries
France
Contacts
Primary ContactPauline Ducatel, Doctor
Outcome results
None listed